Industry
Medical - Diagnostics & Research
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Loading...
Open
1.33
Mkt cap
199M
Volume
206K
High
1.40
P/E Ratio
-3.70
52-wk high
2.21
Low
1.33
Div yield
N/A
52-wk low
1.11
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 4:17 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 11:13 am
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 10:06 am
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 10:03 am
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
October 04, 2024 | 9:49 am
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 5:56 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 9:26 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.